concept

DONANEMAB

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about DONANEMAB: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

97Connections

0Hypotheses

4Analyses

50Outgoing

25Incoming

0Experiments

5Debates

No summary available yet.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	DONANEMAB
Key Genes/Proteins	AMYLOID, AMYLOID-BETA, APOE, APP
Related Diseases	ALZHEIMER, ALZHEIMER'S DISEASE, AMYLOID PLAQUES, AUTOPHAGY, COGNITIVE DECLINE

Wiki Pages (1)

Knowledge base pages for this entity

Canonical Page

Donanemab Dosing Regimens Phase 3 for Early Alzheimer's (NCT05738486)

clinical · 1337 words

→

Pathway Diagram

graph TD
    DONANEMAB["DONANEMAB"]
    DONANEMAB -->|"treats"| Cognitive_Decline["Cognitive Decline"]
    DONANEMAB -->|"targets"| Amyloid_Beta["Amyloid Beta"]
    DONANEMAB -->|"targets"| Amyloid__["Amyloid-beta"]
    DONANEMAB -->|"binds_to"| amyloid__["amyloid-beta"]
    DONANEMAB -->|"treats"| Alzheimer_s_disease["Alzheimer's disease"]
    DONANEMAB -->|"targets"| AMYLOID_BETA["AMYLOID-BETA"]
    DONANEMAB -->|"treats"| Early_Stage_Alzheimer_s_Diseas["Early-Stage Alzheimer's Disease"]
    ADUCANUMAB["ADUCANUMAB"] -->|"target for"| DONANEMAB
    AMYLOID["AMYLOID"] -->|"implicated in"| DONANEMAB

Outgoing (72)

Target	Relation	Type	Str
ad_clinical_trial_failures:donanemab	data_in	dataset_row	0.00
ad_clinical_trial_failures:donanemab	data_in	dataset_row	0.00
amyloid_plaques	clears	pathological_structure	0.00
Amyloid-beta	targets	protein	0.95
Amyloid β	targets	protein	0.95
Amyloid beta	targets	protein	0.95
Cognitive Decline	treats	phenotype	0.95
Amyloid-Β	targets	protein	0.95
Alzheimer's disease	treats	disease	0.95
Alzheimer Disease	treats	disease	0.95
amyloid-β	binds_to	protein	0.95
Early Symptomatic Alzheimer Disease	treats	phenotype	0.95
Amyloid-β	targets	protein	0.95
Disease Progression	inhibits	process	0.95
Amyloid Clearance	promotes	process	0.95
amyloid-β	targets	compound	0.92
Amyloid clearance	promotes	process	0.92
Aria-E	causes	phenotype	0.92
Amyloid-Beta	targets	protein	0.90
Functional Progression	inhibits	phenotype	0.90
ARIA-E	causes	phenotype	0.90
amyloid pathology	inhibits	mechanism	0.90
Amyloid plaque clearance	causes	phenotype	0.90
Alzheimer's_disease	associated_with	disease	0.90
Early-Stage Alzheimer's Disease	treats	disease	0.90
Alzheimer disease	therapeutic_target_for	disease	0.90
Aβ accumulation	therapeutic_target_for	mechanism	0.90
Amyloid Pathology	targets	mechanism	0.90
AMYLOID-BETA	targets	protein	0.90
Alzheimer'S Disease	treats	disease	0.90
amyloid plaques	targets	process	0.90
Alzheimer's Disease	treats	disease	0.85
Mild Dementia	treats	phenotype	0.85
Mild Cognitive Impairment	treats	disease	0.85
ARIA-H	causes	phenotype	0.85
Aria-H	causes	phenotype	0.82
LECANEMAB	therapeutic_target	drug	0.80
Amyloid Reaccumulation	modulates	process	0.75
Alzheimer's Disease	treats	disease	0.75
Tau pathology resolution	causes	phenotype	0.70
cognitive decline	modulates	phenotype	0.70
brain amyloid	causes	phenotype	0.70
AUTOPHAGY	activates	phenotype	0.70
AUTOPHAGY	regulates	phenotype	0.70
autophagy pathway	modulates	pathway	0.65
ADUCANUMAB	treats	drug	0.65
ADUCANUMAB	causes	drug	0.65
AMYLOID	activates	protein	0.65
AMYLOID	treats	protein	0.65
TAU	activates	protein	0.65

Incoming (25)

Source	Relation	Type	Str
ad_clinical_trial_failures:donanemab	data_in	dataset_row	0.00
ad_clinical_trial_failures:donanemab	data_in	dataset_row	0.00
37459141	increased risk of	paper	0.90
37459141	significantly slowed	paper	0.90
37459141	designed to clear	paper	0.90
37459141	reduced decline in	paper	0.90
37459141	achieved treatment effect in	paper	0.90
ADUCANUMAB	therapeutic_target	drug	0.50
NEUROINFLAMMATION	associated_with	phenotype	0.50
INFLAMMATION	associated_with	phenotype	0.50
DONEPEZIL	associated_with	drug	0.45
RIVASTIGMINE	associated_with	drug	0.45
COGNITIVE DECLINE	associated_with	phenotype	0.45
LECANEMAB	associated_with	drug	0.45
ADUCANUMAB	associated_with	drug	0.45
AMYLOID	associated_with	protein	0.45
GANTENERUMAB	associated_with	drug	0.45
ALZHEIMER	associated_with	disease	0.45
CRENEZUMAB	associated_with	drug	0.45
SOLANEZUMAB	associated_with	drug	0.45
DEMENTIA	associated_with	disease	0.45
AMYLOID PLAQUES	associated_with	phenotype	0.45
AMYLOID-BETA	associated_with	protein	0.45
AMYLOID	therapeutic_target	protein	0.35
ALZHEIMER'S DISEASE	associated_with	disease	0.35